Loading
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Journal article
Frontiers in Immunology · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This case report describes a single patient with progressive radiation pneumonitis after combined thoracic radiotherapy and pembrolizumab who exhibited clinical and radiographic improvement after salvage therapy with corticosteroids, tofacitinib (JAK inhibitor), and nintedanib (anti-fibrotic agent), accompanied by declining inflammatory biomarkers. The concurrent administration of three agents and lack of a control group preclude attribution of benefit to any single intervention or validation of the proposed mechanism. The case raises a hypothesis warranting prospective investigation in appropriately selected patients with immune-mediated radiation pneumonitis refractory to corticosteroids alone.
Case report. Single 65-year-old male with esophageal cancer presenting with progressive radiation pneumonitis after concurrent thoracic radiotherapy and pembrolizumab, with inadequate response to moderate-dose systemic corticosteroid therapy.. Intervention: Salvage therapy comprising corticosteroids, tofacitinib (JAK inhibitor), and nintedanib (anti-fibrotic agent)..
65-year-old male with esophageal cancer developed progressive radiation pneumonitis after pembrolizumab and thoracic radiotherapy despite moderate-dose corticosteroid therapy. Laboratory evaluation demonstrated hyper-inflammatory phenotype with elevated interleukin-6, ferritin, and C-reactive protein levels. Salvage regimen of corticosteroids, tofacitinib, and nintedanib was associated with symptomatic improvement, declining inflammatory biomarkers, and near-complete radiographic resolution.
No follow-up duration specified; durability of response and long-term safety unknown. Transient diarrhea occurred after nintedanib initiation and improved after dose reduction; no clinically evident severe treatment-related adverse events during follow-up.
This case suggests a potential salvage approach for corticosteroid-refractory progressive radiation pneumonitis with immune-mediated features, but the concurrent use of three agents and single-patient design prevent attribution of benefit to any specific component or generalization to other patients. Prospective controlled studies are needed before clinical adoption.
A single case report with clinical improvement and biomarker response, but no control group, no prospective design, and no evidence of safety or efficacy beyond one patient.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests a potential salvage approach for corticosteroid-refractory progressive radiation pneumonitis with immune-mediated features, but the concurrent use of three agents and single-patient design prevent attribution of benefit to any specific component or generalization to other patients. Prospective controlled studies are needed before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Sequential or concurrent thoracic radiotherapy and immune checkpoint inhibitors (ICIs) increase the risk of severe overlapping pulmonary toxicity. Progressive pneumonitis after thoracic radiotherapy and ICI exposure remains a clinically challenging condition, particularly when it shows an inadequate response to systemic corticosteroid therapy. We report a 65-year-old man with esophageal cancer who developed progressive radiation pneumonitis with possible immune-mediated contribution after pembrolizumab therapy and thoracic radiotherapy. Despite moderate-dose systemic corticosteroid therapy, he experienced rapid clinical and radiographic deterioration. Laboratory evaluation showed a hyper-inflammatory phenotype, with elevated interleukin-6, ferritin, and C-reactive protein levels. Based on this hyper-inflammatory profile, we initiated a hypothesis-driven salvage regimen comprising corticosteroid therapy, the JAK inhibitor tofacitinib, and nintedanib. This intervention was associated with symptomatic improvement, declining inflammatory biomarkers, and near-complete radiographic resolution. No clinically evident severe treatment-related adverse events were observed during follow-up. Transient diarrhea occurred after nintedanib initiation and improved after dose reduction. This case suggests that biologically rational integration of JAK inhibition and anti-fibrotic therapy may be considered as a hypothesis-driven salvage approach in selected patients with progressive radiation pneumonitis with possible immune-mediated contribution after inadequate response to systemic corticosteroid therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.